Chennai Journal

“Myopia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myopia Market.

The Myopia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myopia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myopia treatment therapies with a considerable amount of success over the years. 
• Myopia companies working in the treatment market are Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Sydnexis, Inc., Nevakar, Inc., and others, are developing therapies for the Myopia treatment 

• Emerging Myopia therapies such as – STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127l, SYD-101, NVK-002, and others are expected to have a significant impact on the Myopia market in the coming years.   
• In August 2021, In Europe, the Middle East, and Africa (EMEA), Santen and Sydnexis have announced an exclusive agreement to licence SYD-101, an investigational treatment for progressive childhood myopia. SYD-101 is an investigational low-dose atropine sulphate ophthalmic solution created to increase treatment continuity by achieving efficacy, stability, and reducing discomfort. A multi-center Phase III clinical trial (STAARstudy) is currently being conducted on it in the US and Europe
• In August 2021, A $45 million Series B financing headed by Visionary Ventures, Blue Stem Capital, and SC Master Fund was announced by Sydnexis. The funding will be used to support the company’s flagship candidate, SYD-101, until the end of the key Phase 3 STAAR study for the treatment of progressive myopia in children, which has a fully enrolled study population

Myopia Overview

Shortsightedness, often known as myopia, is the most prevalent type of refractive error (RE) in which a person can see clearly up close but not clearly at a distance. Here, distance is defined as anything farther than three feet, and close is defined as at reading distance, or around 35 to 40 cm. When the accommodation function is at rest, light rays from infinity cannot focus in the retina; instead, they are focused in front of the retina.

Get a Free Sample PDF Report to know more about Myopia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myopia-pipeline-insight

Emerging Myopia Drugs Under Different Phases of Clinical Development Include:

• STN-1013400: Santen Pharmaceutical
• SHJ002: Sunhawk Vision Biotech
• EXP039: Nevakar, Inc.
• NVK002: Vyluma
• MicroPine: Eyenovia
• CBT-009: Cloudbreak Therapeutics, LLC
• IVMED 85: iVeena Delivery Systems
• DE 127: Santen Pharmaceutical
• SYD-101: Sydnexis, Inc.
• NVK-002: Nevakar, Inc.

Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Myopia Pipeline Therapeutics Assessment

• Myopia Assessment by Product Type
• Myopia By Stage and Product Type
• Myopia Assessment by Route of Administration
• Myopia By Stage and Route of Administration
• Myopia Assessment by Molecule Type
• Myopia by Stage and Molecule Type

DelveInsight’s Myopia Report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myopia product details are provided in the report. Download the Myopia pipeline report to learn more about the emerging Myopia therapies

Some of the key companies in the Myopia Therapeutics Market include:

Key companies developing therapies for Myopia are – EssilorLuxottica, Johnson & Johnson Vision, CooperVision, Alcon, Bausch + Lomb, Carl Zeiss Meditec, Hoya Corporation, Nikon Corporation, Topcon Corporation, Seiko Optical Products, Menicon Co., Ltd., Shamir Optical Industry Ltd., Visioneering Technologies, Inc., HOYA Vision Care, Nevakar Inc., WuXi AppTec, Ginkgo Bioworks, Zeiss Group, Novartis AG, Allergan (now part of AbbVie), and others.

Myopia Pipeline Analysis:

The Myopia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.
• Myopia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myopia drugs and therapies

Myopia Pipeline Market Drivers

• Increase in the prevalence of Myopia, increasing Research and Development activities are some of the important factors that are fueling the Myopia Market.

Myopia Pipeline Market Barriers

• However, cost associated with the treatment, unclear pathogenesis of the disease and other factors are creating obstacles in the Myopia Market growth.

Scope of Myopia Pipeline Drug Insight    

• Coverage: Global
• Key Myopia Companies: Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Sydnexis, Inc., Nevakar, Inc., and others
• Key Myopia Therapies: STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127l, SYD-101, NVK-002, and others
• Myopia Therapeutic Assessment: Myopia current marketed and Myopia emerging therapies
• Myopia Market Dynamics: Myopia market drivers and Myopia market barriers 

Request for Sample PDF Report for Myopia Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services